Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results

PURPOSE: To evaluate the safety and preliminary efficacy of topical rVA576, a dual inhibitor of complement component 5 (C5) and leukotriene B4 (LTB4), in patients with recalcitrant atopic keratoconjunctivitis (AKC) in the open label phase 1 TRACKER clinical trial. METHODS: Three patients diagnosed w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Tabernero, Sara, Fajardo-Sanchez, Julia, Weston-Davies, Wynne, Parekh, Mohit, Kriman, Jaime, Kaye, Stephen, Ahmad, Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196439/
https://www.ncbi.nlm.nih.gov/pubmed/34116700
http://dx.doi.org/10.1186/s13023-021-01890-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196439/
https://www.ncbi.nlm.nih.gov/pubmed/34116700
http://dx.doi.org/10.1186/s13023-021-01890-6

Ejemplares similares